SPEARFISH -- From a distance Seth looks like any tired 8-year-old boy taking a nap on a couchA “Thomas the Train” blanket covers him as his head rests on a pillowThen you notice it. A box of medical supplies is lying on a table in front of the brown-haired child. A tube runs to his no

read more>>

A pesky little molecular glitch makes life tough for this little boy whose thirst is so fierce he drinks in his sleepLiam Walter, 5, of Figtree, has a disorder known as nephrogenic diabetes insipidus, which interferes with his kidney's ability to conserve waterSufferers urinate on average every h

read more>>

ALLSCHWIL/BASEL, SWITZERLAND -- Actelion Ltd (SIX: ATLN) announced today that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for Zavesca® (miglustat) for the treatment of progressive The FDA

read more>>

London, UK -- The Board of Ark Therapeutics Group plc ("Ark" or "the Company") today announces an update relating to the Marketing Authorisation Application ("MAA") for its brain cancer treatment, Cerepro®Following a presentation to the EMEA's Scientific Advisory Group on Oncology ("SAG-O") as

read more>>

ABBOTT PARK, Ill., and REDWOOD CITY, Calif. -- Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipelineAbbott will acquire Facet for $27 per share in cash for

read more>>

CLAREMONT, Calif. -- Among the 14 groups at the Food and Drug Administration workshop that filed applications for orphan drug designation, Chris Hempel—part of a small team—stood out in her long-sleeved T-shirt and jeansThe corporate potential applicants at the event tended to guard th

read more>>

SEATTLE -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disordersOmeros has demonstrated a previously unknown link between phosphodies

read more>>

BRISBANE, Calif. -- InterMune, Inc. (Nasdaq: ITMN) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (I

read more>>

THESSALONIKI, Macedonia, Greece -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced data which showed that augmentation with ketone bodies significantly improved cognitive function in Alzheimer's disease (AD) patientsAn early fea

read more>>

LAS VEGAS -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com), is focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationallyIts

read more>>